Phase 3 Recruiting Network
This phase III trial evaluates whether a web-based intervention called Current Together after Cancer (CTAC) works to increase the number of patients with surgically removed (resected) colorectal cancer who receive surveillance care that al…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT07018869
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
- Providence Hood River Memorial Hospital — Hood River, Oregon
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in Oregon: - St Charles Medical Center — Bend, Oregon
- Oregon Health And Science University — Portland, Oregon
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Oregon: - Oregon Health And Science University — Portland, Oregon
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Oregon: - Oregon Health and Science University — Portland, Oregon
Phase 3 Recruiting Industry
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard…
Sponsor: AbbVie
NCT ID: NCT07525206
Sites in Oregon: - Compass Oncology - Rose Quarter /ID# 280127 — Portland, Oregon
Phase 2 Recruiting Academic/Other
This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Oregon: - Saint Charles Health System — Bend, Oregon
- Oregon Health and Science University — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Oregon: - Oregon Health & Science University (OHSU) — Portland, Oregon
Phase 2 Recruiting Academic/Other
This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main g…
Sponsor: SCRI Development Innovations, LLC
NCT ID: NCT07011576
Sites in Oregon: - Oncology Associates of Oregon - Primary — Eugene, Oregon
- Northwest Cancer Specialists - Compass — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Oregon: - Providence Cancer Center Oncology and Hematology Care- Eastside — Portland, Oregon
Phase 2 Recruiting Academic/Other
Rectal cancer patients who do not achieve a complete response to standard of care chemotherapy and radiation often require surgical resection as part of curative intent therapy. This study will evaluate whether additional "focal" radiation…
Sponsor: University of Colorado, Denver
NCT ID: NCT07292298
Sites in Oregon: - Oregon Health and Sciences University — Portland, Oregon
Phase 2 Recruiting Industry
In the United States, colorectal cancer ranks second to lung cancer as a cause of cancer death and is the third most commonly occurring cancer in both men and women. Colorectal cancer in most cases develops slowly over a period of years, s…
Sponsor: Jubaan Ltd.
NCT ID: NCT06612281
Sites in Oregon: - The Oregon Clinic Gastroenterology-East — Portland, Oregon
Phase 2 Recruiting Academic/Other
This phase II trial tests how well olanzapine works in managing cancer cachexia in patients experiencing esophagogastric, hepatopancreaticobiliary, colorectal, or lung cancer that may have spread from where it first started to nearby tissu…
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT05705492
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
Phase 1 Recruiting Industry
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker…
Sponsor: Hoffmann-La Roche
NCT ID: NCT04929223
Sites in Oregon: - Hematology Oncology Salem — Salem, Oregon
Phase 1 Recruiting Industry
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
Sponsor: AstraZeneca
NCT ID: NCT05877599
Sites in Oregon: - Research Site — Portland, Oregon
Phase 1 Recruiting Industry
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Sponsor: AstraZeneca
NCT ID: NCT06218914
Sites in Oregon: - Research Site — Portland, Oregon
Phase 1 Recruiting Industry
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Sponsor: ALX Oncology Inc.
NCT ID: NCT07085091
Sites in Oregon: - ALX Center 6 — Portland, Oregon
Phase 1 Recruiting Industry
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered o…
Sponsor: MOMA Therapeutics
NCT ID: NCT06974110
Sites in Oregon: - Investigative Site #121 — Portland, Oregon
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
- Kaiser Permanente Northwest — Portland, Oregon
NA Recruiting Academic/Other
This study seeks to learn whether using the PAGODA algorithm to guide chemotherapy dosing will lower the chance of unplanned delays during chemotherapy for cancer in the gastrointestinal system compared to usual care.
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07283939
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Alphonsus Cancer Care Center-Ontario — Ontario, Oregon
NA Recruiting Academic/Other
This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal pol…
Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT05612347
Sites in Oregon: - Kaiser Permanente Northwest — Portand, Oregon
- Oregon Health & Science University (Knight Cancer Institute) — Portland, Oregon
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Oregon: - Oregon Health Sciences University — Portland, Oregon
Recruiting Academic/Other
Colon cancer is the second most common cancer in men and women. It is a disease that can be prevented if it is found early. Colonoscopy is still the best screening tool for colon cancer and the polyps that turn into colon cancer. However, …
Sponsor: University of Michigan Rogel Cancer Center
NCT ID: NCT00843375
Sites in Oregon: - Oregon Health and Science University — Portland, Oregon
NA Recruiting Academic/Other
This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad…
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT04494945
Sites in Oregon: - Providence Portland Medical Center — Portland, Oregon
- OHSU Knight Cancer Institute — Portland, Oregon